natgillin/translations-raw huggingface dataset:
X- is a physiologically acceptable anion selected from the group consisting of chloride, bromide, iodide, hydroxide, sulfate, nitrate, phosphate, acetate, trifluoroacetate, fumarate, citrate, tartrate, oxalate, succinate, mandelate, methanesulfonate and p-toluenesulfonate. 
X- je fiziološki prihvatljiv anion kojeg se bira iz skupine koju čine klorid, bromid, jodid, hidroksid, sulfat, nitrat, fosfat, acetat, trifluoracetat, fumarat, citrat, tartarat, oksalat, sukcinat, mandelat, metansulfonat i p-toluensulfonat.
A dermal matrix formulation produced by using method according to claim 1, characterized in that it comprises an antioxidant-loaded hyaluronic acid (HA)-dipalmitoylphosphatidylcholine (DPPC) micro particles in collagen-laminin scaffold. 
Formulacija dermalnog matriksa dobivena postupkom u skladu s patentnim zahtjevom 1, naznačena time što sadrži mikročestice od hijaluronske kiseline (HA) 1 dipalmitolifosfatidilkolina (DPPC) napunjene antioksidansom u kolagensko-lamininskoj okosnici.
Viewed from one aspect the invention provides a pyrethroid or pyrethrin for use in a method of treatment of farmed fish to combat infestation by multicellular ectoparasites with exoskeletons which method comprises topically exposing farmed fish, especially fish in cages, to a first and a second sea lice treatment agent sequentially, said first sea lice treatment agent being a carbamate or organophosphate and said second sea lice treatment agent being a pyrethroid or pyrethrin, wherein exposure to the first sea lice treatment agent is effected 10 minutes to 12 hours before exposure to the second sea lice treatment agent. 
HR P20130233 T1 PATENTNI ZAHTJEVI u Organofosfat ili karbamat za uporabu u postupku tretmana uzgajanih riba radi borbe protiv infestacije višestaničnim ektoparazitima s tvrdim vanjskim skeletom (egzoskelet), taj postupak obuhvaća uzastopni topikalni tretman uzgajanih riba s prvim i drugim sredstvom protiv morskih uši, to prvo sredstvo protiv morskih uši je karbamat ili organofosfat i drugo sredstvo protiv morskih uši je piretroid ili piretrin, pri čemu izloženost prvom sredstvu protiv morskih uši traje 10 minuta do 12 sati prije izlaganja drugom sredstvu protiv morskih uši.
Acid secretion is stimulated with infusion during 2.5-4 h (1.2 ml/h, subcutaneously) of pentagastrin and carbachol (20 and 110 nmol/kg·h, respectively), during which time gastric secretions are collected in 30-min fractions. 
Lučenje kiseline je stimulirano infuzijom tijekom 2.5-4 h (1.2 ml/h, uzastopno) pentagastrina 1 karbakola (20 1 110 nmol/kg-h), a tijekom toga vremena sakupljane su želučane izlučevine svakih 30-min.
measuring a value of the tension acting on the yarn (F) upstream of said bobbin (2) in a non-invasive way by means of at least one load cell; 
mjerenja vrijednosti napetosti koja djeluje na nit (F) uzvodno navedenog kalema (2) na neinvazivni način uz pomoć najmanje jedne ćelije opterećenja; -
The method of claim 1, wherein the cumulative total amount of serine per unit volume in said medium is greater than 10 mM. 
Postupak prema Zahtjevu 1, što je kumulativna ukupna količina serina po jedinici volumena u spomenutom mediju veća od približno 10 mM.
The subject invention also provides a process for preparing a pharmaceutical product comprising N-ethyl-N-phenyl-1,2,-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide or a salt thereof and a pharmaceutically acceptable carrier, wherein the pharmaceutical product has not more than a total of 0.5% w/w relative to N-ethyl-N-phenyl-1,2,-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide of the oxidation decomposition products 2-Chloro-6-(1-ethyl- N -methyl-2-oxoindoline-3-carboxamido) benzoic acid, 1 H, 3 H -spiro[5-chloro-1-methylquinoline-2,4-dione-3,3'-[1]ethylindolin-[2]-one], and 5-Chloro- N -ethyl-3-hydroxy-1-methyl-2,4-dioxo- N -phenyl-1,2,3,4-tetrahydro-quinoline-3-carboxamide as defined in claim 7. 
Postupak za validaciju šarže farmaceutskog produkta koji sadrži spoj N-etil-N-fenil-1,2-dihidro-4-hidroksi-5-kloro-1-metil-2-oksokinolin-3-karboksamid ili njegovu sol, te farmaceutski prihvatljiv nosilac za distribuciju, naznačen time, da obuhvaća: a) podvrgavanje uzorka šarže ispitivanju stabilnosti; b) određivanje ukupne količine produkta oksidacijskog raspadanja u uzorku šarže nakon ispitivanja stabilnosti: i c) validaciju šarže za distribuciju, samo ako uzorak šarže nakon ispitivanja stabilnosti ne sadrži više od ukupno 0,5 1te2.% produkata oksidacijskog raspadanja N-etil-N-fenil-1,2-dihidro-4-hidroksi-5-kloro-1-metil-2-oksokinolin-3-karboksamida, u odnosu na N-etil-N-fenil-1,2-dihidro-4-hidroksi-5-kloro-1-metil-2-oksokinolin-3-karboksamid.
Methods to generate such a prodrug from a compound of formula I are known to those skilled in the art, and are listed in the references below. 
Postupci za dobivanje takvog prolijeka iz spoja formule I poznati su osobama iz struke i spomenuti su u niže navedenim referencama.
is hydrogen or C1-C6 alkyl optionally substituted by halogen or C1-C6 alkoxy; or R12 and any one of R8, R9, R, R', R10 or R11 together with the atoms to which they are bound may form a 4, 5, 6 or 7 membered azacyclic ring, which ring may optionally be substituted by halogen, cyano, hydroxyl, C1-C6 alkyl or C1-C6 alkoxy; n is 0 or 1; and 
R12 je vodik ili C,-Cg alkil prema potrebi supstituiran s halogenom ili Ci-C$ alkoksi; ili R12 i bilo koji od R8, R9, R, R', R10 ili RI1 zajedno s atomima na koje su vezani, mogu tvoriti 4-, 5-, 6- ili 7člani azaciklički prsten, pri čemu taj prsten može prema potrebi biti supstituiran sa sljedećima: halogen, cijano, hidroksil, Ci-Cg alkil ili C1-Cg alkoksi; nje0ili l;i
A frying fat composition comprising at least 70 wt.% of refined fat; 3-30 wt.% of a red palm oil-component, said red palm oil component being selected from the group consisting of red palm oil, red palm oil fractions and combinations thereof; and from 5 to 100 mg/kg, preferably from 6-50 mg/kg of B-carotene. 
– 0,5-15%, težinski, ulja crvene palme; – 15-75%, težinski, visoko nezasićenog ulja, koje se bira iz skupine koju čine suncokretovo ulje, sojino ulje, ulje iz sjemena uljane repice, ulje iz sjemena pamuka, šafranikino ulje, riblje ulje, kukuruzno ulje, maslinovo ulje, ulje iz sjemena lana i njihove kombinacije; i – 25-60%, težinski, strukturne masti, koju se bira iz skupine koju čine palmino ulje, frakcije palminog ulja, laurinska mast, frakcije laurinske masti, posve hidrogenirano biljno ulje, i njihove kombinacije;
The process of claim 14, wherein after the ferric ion source has completely dissolved, the temperature of the solution is lowered to a range of from 15°C. to 75°C. to prevent hydrolysis of pyrophosphate. 
Postupak prema zahtjevu 14, gdje nakon što se izvor feri iona potpuno otopi, temperatura otopine se smanjuje do raspona od 15%C do 75*C radi hidrolize pirofosfata.
To evaluate the toxicity produced by orally administered compound of formula I when administered daily to female CD-a mice for 4 days, the gastrointestinal toxicity profiles of a compound of formula I is compared with the historical results for gastrointestinal toxicity when gemcitabine is administered orally at 8 mg/kg in a 4-day mouse study. 
Cetverodnevni pregled miševa Kako bi se procijenilo toksičnost koju uzrokuje oralno primijenjeni spoj formule I prilikom svakodnevne primjene na ženkama CD-a miševa tijekom 4 dana, profili gastrointestinalne toksičnosti spoja formule I procijenjeni su uz povijest gastrointestinalne toksičnosti kada je gemcitabin primijenjen oralno u dozi od 8 mg/kg, u četverodnevnom ispitivanju na miševima.
The method according to one or more of claims 8 and 9, characterized in that the temperature of the ribbon of coated paper is kept below 30°C. 
Postupak u skladu s jednim ili oba patentna zahtjeva 4 i 5, naznačen time, da se temperatura vrpce premazanog papira održava ispod 30°C.
In another embodiment L is C(O). 
L je veza ili C(O);
The process of item 15, wherein the temperature of step c) is the target temperature measured using a temperature probe and wherein the curing step starts when the temperature measured using the temperature probe reaches said temperature and the curing step ends either when the heating is stopped or at least reduced and the temperature measured using the temperature probe subsequently drops below said temperature by more than about 10 °C or below about 62 °C, in a plateau-like temperature profile or when the temperature measured using the temperature probe drops below said temperature in a parabolic or triangular temperature profile. 
Postupak prema zahtjevu 15, naznačen time da je temperatura koraka c) ciljana temperatura mjerena korištenjem ispitivača temperature i gdje korak stvrdnjavanja započinje kada temperatura mjerena korištenjem ispitivača temperature dosegne navedenu temperaturu te korak stvrdnjavanja završava ili kada se zaustavi zagrijavanje ili kada je barem smanjeno te temperatura mjerena korištenjem ispitivača temperature naknadno pada ispod navedene temperature za više od oko 10 "C ili ispod oko 62 *C, u temperaturnom profilu nalik platou ili kada temperatura mjerena korištenjem ispitivačem temperature padne ispod navedene temperature u paraboličnom ili trokutastom temperaturnom profilu.
A pharmaceutical product according to claim 1 or 2, wherein said active ingredient is a functional variant of the B2-microglobulin protein presenting at least 80%, and preferably 90% identity with the human B2-microglobulin protein. 
Farmaceutski proizvod u skladu s patentnim zahtjevom 1 ili 2, pri čemu je navedeni aktivni sastojak funkcionalna varijanta proteina B2-mikroglobulina koji pokazuje najmanje 80%, a poželjno 90% identičnosti s ljudskim proteinom B2-mikroglobulinom.
R represents independent from each other hydroxyl, cyano, nitro, halogen, alkyl, alkoxy alkylcarbonyl, alkoxycarbonyl, alkylamine, dialkylamine, alkylcarbonylamine, or alkylcarbamate, and Y represents one of the following groups: 
R predstavlja neovisno jedan od drugoga hidroksil, cijano, nitro, halogen, alkil, alkoksi alkilkarbonil, alkoksikarbonil, alkilamin, dialkilamin, alkilkarbonilamin, alkilkarbamat, Y predstavlja jednu od sljedećih skupina: 15
Process according to claim 9, characterised in that step d) is carried out by passing the gas stream through the section of the reactor where the heat exchanger (4) is externally located, wherein the fluid that is used in said heat exchanger (4) is a thermal oil with an intake temperature in said heat exchanger (4) of 250ºC and an outlet temperature of 350ºC, thereby preventing condensation on the walls of the section, where said heat exchanger (4) is located, of the tars that may remain in the gas stream. 
Postupak u skladu s patentnim zahtjevom 9, naznačen time što se korak d) provodi propuštanjem struje plina kroz odjeljak reaktora gdje je izmjenjivač topline (4) smješten izvana, gdje je fluid kojeg se upotrebljava u navedenom izmjenjivaču topline (4) toplinsko ulje, gdje je ulazna temperatura u navedenom izmjenjivaču topline (4) 250%, a izlazna temperatura je 350%C, čime se sprječava kondenziranje katrana koji bi mogli preostati u struji plina na stijenkama odjeljka gdje je smješten navedeni izmjenjivač topline (4).
A synergistic herbicidal mixture as claimed in claims 1 to 2 in which the sulfonamide is selected from the group consisting of florasulam, flumetsulam, metosulam, penoxulam, cloransulam-methyl, and diclosulam, including their respective isomers as well as their respective environmentally compatible salts or esters or amides or other derivatives. 
Sinergistička herbicidna smjesa prema patentnom zahtjevu 1, naznačena time što su kloroacetamidi, uključujući njihove odgovarajuće izomere kao i njihove odgovarajuće sa životnom sredinom kompatibilne soli, estere, amide 1li druge derivate, izabrani iz grupe koju čine metazaklor, metolaklor i dimetenamid.
The fuel pump nozzle as claimed in claim 5, wherein the lever (10) includes a release actuating surface (24) for co-operating with the at least one hold-open catch (14). 
Pištolj za istakanje goriva prema zahtjevu 5, naznačen time da ta polugica (10) sadrži površinu za otpuštanjeaktiviranje (24), koja predstavlja podlogu za djelovanje jezičca za držanje u otvorenom položaju (14).
The organic extracts were combined, dried over MgSO4, filtered and evaporated. 
Organski ekstrakti se spoje, osuše preko MgSO,, filtriraju i upare.
The formulation of claim 10, wherein the tonicity modifier is present in the formulation at a concentration sufficient for the formulation to be approximately isotonic. 
Formulacija iz patentnog zahtjeva 10, pri čemu je modifikator tonusa prisutan u formulaciji u koncentraciji dovoljnoj za približno izotoničnu formulaciju.
realizing data consistency between the values of the back copies of the data items (D1, D2, D3) based on the information stored in the log files stored on the number of network nodes (1, 2, 3, 4, 5, 6). 
- < Ostvarivanje dosljednosti podataka između vrijednosti sigurnosne kopije podatakovne stavke (D1, D2, D3) na temelju podataka pohranjenih u dnevniku rada pohranjenom na brojnim mrežnim čvorovima (1, 2, 3, 4, 5,
BRIEF DESCRIPTION OF THE DRAWINGS FIG. 1 is a schematic view from above of the sanding element according to the invention. 
Slika 1 je shematski prikaz elementa za brušenje koji je u skladu s ovim izumom, gledan s gornje strane.
Apoaequorin for use according to claim 2, wherein the injection is an intra-hippocampal injection. 
3. < Apoekvorin za uporabu prema zahtjevu 2, naznačen time, da se kod injekcije radi o intra-hipokampalnoj injekciji.
The rounded end 8 enables the user to accurately detect contact with the cervix. 
Zaobljeni kraj 8 omogućava korisnici da točno otkrije dodir s grličem maternice.
The device according to claim 1 wherein the dry powder comprises talc silicified, in an amount of 2 mg per 100 mg of dry powder, wherein said talc silicified comprises talc purified and colloidal silicon dioxide in an amount of 0.667 mg of talc purified and 1.333 mg of colloidal silicon dioxide for 2 mg of talc silicified. 
Uređaj prema bilo kojem od zahtjeva 1-6, naznačen time da suhi prah sadrži silificirani talk, poželjno u količini od 2 mg po 100 mg suhog praha, pri čemu navedeni silificirani talk poželjno sadrži pročišćeni talk i koloidni silicijev dioksid u poželjnoj količini od 0,667 mg pročišćenog talka 1 1,333 mg koloidnog silicijeva dioksida za 2 mg silificiranog talka.
fractionating the first stage effluent and the second stage effluent to recover at least one distillate hydrocarbon fraction and a resid hydrocarbon fraction; feeding the resid hydrocarbon fraction to a solvent deasphalting unit (32) to provide an asphaltene fraction and the deasphalted oil fraction. The process of claim 1, wherein hydrocracking a resid comprises: 
dovođenje efluenta iz prvog stupnja i iz drugog stupnja u sustav za odvajanje (26); frakcioniranje efluenta iz prvog stupnja i efluenta iz drugog stupnja u sustavu za odvajanje (26) da bi dobila najmanje jedna ugljikovodična frakcija destilata i frakcije ugljikovodičnog ostatka; te dovođenje ugljične frakcije ostatka u jedinicu za deasfaltiranje otapalom (32) kako bi se dobila asfaltenska frakcija i deasfaltirana uljna frakcija, pri čemu hidrokrekiranje ostatka obuhvaća:
A composition according to claim 1, which comprises as component (A) the compound 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-dichloromethylidene-benzonorbornene-5-yl)amide and as component (B) a compound selected from difenoconazole, propiconazole, cyproconazole and epoxiconazole. 
Pripravak prema zahtjevu 1, naznačen time da sadrži kao komponentu (A) spoj 3-difluorometil-1-metil-1Hpirazol-4-karboksilna kiselina (9-diklorometiliden-benzonorbornen-5-il)amid, a kao komponentu (B) fludioksonil.
Cy is a phenyl group or a pyridyl group, wherein the phenyl group or the pyridyl group may have one to three substituents, which may be the same or different, selected from the group consisting of a halogen atom, a cyano group, a C1-6 alkyl group, a C1-6 alkoxy group, wherein the C1-6 alkyl group or the C1-6 alkoxy group may be substituted with one to three halogen atoms, and a C2-6 alkanoyl group. 
Cy je arilna skupina ili piridilna skupina, pri čemu arilna skupina ili piridilna skupina mogu imati jednog do tri supstituenta, koji mogu biti jednaki ili različiti, izabrani iz skupine koja se sastoji od atoma halogena, cijano skupine, Cis alkilne skupine, Cig alkoksi skupine, pri čemu Cig alkilna skupina ili C,g alkoksi skupina mogu biti zamijenjene sa jednim do tri atoma halogena, i C2.4 alkanoilne skupine.
The method for installation and laying of a waterproof liner according to claim 1, comprising providing a watertight connection device between the distal ends of the flexible sealing flaps of adjoining waterproof tubular panels, wherein each waterproof tubular panel consists of a single waterproof membrane in geosynthetic material. 
Postupak ugradnje i polaganja vodonepropusne obloge u skladu s patentnim zahtjevom 1, naznačen time, da se postavlja vodonepropusni spojni uređaj (44; 45) između savitljivih preklopa (26) susjednih vodonepropusnih ploča (14), pri čemu se svaka vodonepropusna ploča (14) sastoji od jedne vodonepropusne membrane od geosintetičkog materijala.
The composition of claim 60, wherein an additional substance selected from a nucleic acid molecule for the delivery of genes for gene therapy; a nucleic acid molecule for the delivery of antisense RNA, RNAi or siRNA for suppressing a gene in an NK cell; or a toxin or a drug for the targeted killing of NK cells is additionally incorporated into said liposome. 
Oblik prema zahtjevu 60, gdje je u liposom dodatno inkorporirana dodatna tvar izabrana između molekule nukleinske kiseline za dopremu gena za gensku terapiju; molekule nukleinske kisline za dopremu nekodirajuće RNA, RNAi ili siRNA za supresiju gena u NK stanici.
The recombinant RSV antigen of any one of claims 1-6, wherein the F2 domain comprises at least a portion of an RSV F protein polypeptide corresponding to amino acids 26-105 of the reference F protein precursor polypeptide (F0) of SEQ ID NO:2. 
Rekombinantni antigen RSV u skladu s bilo kojim od patentnih zahtjeva 1-6, naznačen time što domena F2 sadrži u najmanju ruku dio polipeptida proteina F iz RSV koji odgovara aminokiselinama 26-105 u polipeptidu preteče referentnog proteina F (F0) sa SEQ ID NO:2.
To improve this situation, a metallic wire is combined with a textile yarn or filament, generally by winding or twisting. 
Da bi se poboljšalo takvo stanje, metalne žice sc kombiniraju s tekstilnom pređom ili s nitima, općenito obavijanjem ili uvijanjem.
inhibits or reduces allodynia in an in vivo model of osteoarthritis; or (viii) does not cross-react with other GFR co-receptors for RET. 
inhibira ili smanjuje alodiniju u in vivo modelu osteoartritisa; ili (viii) ne stupa u unakrsnu reakciju s drugim GFR koreceptorima za RET.
A frame according to claim 3, further comprising a motor apparatus, which delivers driving power to at least one of said mountings and is arranged on at least one of said lateral modules. A frame according to claim 3, wherein said mounting is rigidly constrained to said bearing portion. 
Okvir u skladu sa bilo kojim od patentnih zahtjeva od 5 do 7 1 koji sadrži, osim toga, aparaturu (22) motora, koja je sposobna isporučiti pogonsku snagu najmanje jednom od spomenutih držača (18) i poželjno je postavljena na najmanje jedan od spomenutih lateralnih modula (3).
a compound selected from the group consisting of sulfonylureas, including their respective isomers a s well as their respective environmentally compatible salts or esters or amides or other derivatives; and 
A) imazamoks, uključujući njegove odgovarajuće izomere kao i njegove odgovarajuće sa životnom sredinom kompatibilno soli, estere, amide ili druge derivate; i
The cyclohexenone compound as claimed in claim 17, wherein the organic solvents are selected from the group consisting of alcohols, esters, alkanes, and alkyl halides. 
Cikloheksenonski spoj prema patentnom zahtjevu 17, naznačen time, da se organska otapala odabiru iz skupine koja se sastoji od alkohola, estera, alkana i alkil-halogenida.
A microencapsulated bacterial consortium, according to claim 3, wherein the encapsulating agents are isolated protein from milk serum with 90% protein, maltodextrin with a dextrose equivalent of 10, arabic gum and combinations thereof. 
Mikroenkapsulirani bakterijski konzorcij, prema zahtjevu 3, pri čemu su agensi za enkapsulaciju izolirani proteini iz mliječnog seruma s 90 % proteina, maltodekstrin s ekvivalentom dekstroze od 10, guma arabika i njihove kombinacije.
It is a further object of the present invention to provide the use of the ultra-fast setting cement composition such as described hereabove to accelerate the setting of Portland cements. 
Upotreba ultrabrzo vežuće cementne smjese u skladu s bilo kojim od prethodnih patentnih zahtjeva 1 do 9, naznačena time što su cementne smjese namijenjene ubrzavanju vezanja portland cementa.
Pharmaceutical combination for use according to claim 1 or 2, in which the pharmaceutically acceptable salt of the compound N -[4-[2-(2-amino-4,7-dihydro-4-oxo-1 H -pyrrolo[2,3- d]pyrimidin-5-yl)ethyl]benzoyl]-L-Glutamic acid is its disodium salt form. 
Farmaceutska kombinacija za uporabu prema zahtjevu 1 ili 2, naznačena time, da farmaceutski prihvatljiva sol spoja N-[4-[2-(2-amino-4,7-dihidro-4-okso-1H-pirolo[2,3-d]pirimidin-5-il)etil]benzoil]-L-glutaminske kiseline, predstavlja njegov oblik dinatrijeve soli.
In a 8th aspect according to any one of the preceding aspects from the 3rd to the 7th the predetermined number of thermoregulation fluid distributors comprises a plurality of distinct distributors positioned outside the mould and configured for directing the thermoregulation fluid at least towards respective portions of an external lateral surface of the mould itself. 
9 zadani broj razdjelnika (33) termoregulacijskog fluida, smješten izvan kalupa (2) i konfiguriran za usmjeravanje termoregulacijskog fluida u najmanju ruku prema zadanim dijelovima vanjske bočne površine samog kalupa (2), 9
Thus, the outputs of the receiver, which appear along the connection strip labeled "power supply connection and command exits", in Figure 2, are connected in parallel with the existing controls of the boat. 
Tako su izlazi iz prijemnika koji se nalaze uzduž trake za spajanje s oznakom «priključak napajanja i upravljački izlazi», na slici 2, spojeni paralelno postojećim kontrolama na plovilu.
the transforming growth factor alpha, the epidermal growth factor and the HER2 marker gene, 
- < amfiregulin-marker-genom, marker-genom faktora epidermalnog rasta i marker-genom alfa faktora transformacije rasta,
Netupitant or a pharmaceutically acceptable salt thereof, for use in treating chemotherapy induced nausea and vomiting ("CINV") induced by highly emetogenic chemotherapy, for a period of five consecutive days in a patient in need thereof, wherein said netupitant is administered in a therapeutically effective amount which is effective to treat nausea and vomiting during the acute and delayed phases of emesis, enters the systemic circulation, crosses the blood brain barrier and occupies at least 70% of NK1 receptors in the striatum seventy-two hours after said administration. 
navedeni netupitant ili njegova farmaceutski prihvatljiva sol je prisutan/prisutna u terapeutski efikasnoj količini koja je efikasna za liječenje mučnine i povraćanja u toku akutne i odgođene faze emezisa, i koja ulazi u sustavnu cirkulaciju, prolazi kroz krvno moždanu barijeru i zauzima najmanje 70% NK1 receptora u striatumu sedamdeset i dva sata poslije navedene primjene;
The method of claim 5, wherein said extraction step comprises at least one separating step to remove fibrilar debris subsequent to, or instead of, said washing step and which is carried out by centrifugation or phase separation. 
Postupak prema bilo kojem zahtjevu od 1 do 5, naznačen time da navedeni korak ekstrakcije sadrži barem jedan korak razdvajanja radi uklanjanja vlaknastih nečistoća poslije, ili umjesto, navedenog koraka ispiranja 1 koji se provodi centrifugiranjem ili odvajanjem faza.